This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	X-box binding protein 1 (XBP1)	<p>Studies in mice and patient samples suggest inhibiting the XBP1 branch of the unfolded protein response could help treat triple-negative breast cancer (TNBC). In mouse xenograft models of TNBC, shRNA against <i>XBPI</i> decreased tumor growth, lung metastasis and tumor relapse compared with control shRNA. In two independent TNBC cohorts, an expression signature encompassing 96 XBP1-regulated genes was associated with decreased relapse-free survival. Next steps include establishing preclinical and genetic models to validate the XBP1 pathway as a therapeutic target.</p> <p>SciBX 7(16); doi:10.1038/scibx.2014.452 Published online April 24, 2014</p>	Patent application filed; unavailable for licensing	<p>Chen, X. <i>et al. Nature</i>; published online March 23, 2014; doi:10.1038/nature13119 Contact: Laurie H. Glimcher, Weill Cornell Medical College, New York, N.Y. e-mail: lglimche@med.cornell.edu</p>